Please find enclosed the above-mentioned manuscript, which we submit for publication as an Original Article in the journal of Sexually Transmitted Diseases.
1.
The MLST system is based on 5 variable genes and the details of the methods for amplification, sequencing, etc have been published elsewhere. Two methods are used to perform ompA typing: one is based on RFLP patterns and the other is based on direct sequencing of a nested PCR product. In Table 1 the column labeled ompA contains numbers which I am guessing represent ompA sequence based genotype assignments. This is confusing as neither the methods section nor the Table footnote provides Furthermore, the relationship between the 2 ompA genotyping systems is not clear. For example in the results we are told that the "conventional" ompA typing system resulted in 18 genotypes. Depending on your point of view, either of the 2 genotyping systems could the "conventional" system. The authors need to clarify why they present the results of 2 ompA genotyping systems and how they are using the data in the analysis.
If the data from one of the ompA genotyping systems is not being used in this analysis then that data should be removed from Table 1 for the sake of clarity.
Answer: We agree and have therefore removed the RFLP results and RFLP methodology description from the manuscript. The serovar designations are now based on the ompA sequence instead.
2.
Line 151 -"No MLST profile represented by more than one isolate was found within a single clinical category only." This sentence does not make sense.
Answer: The sentence has been changed to: "All MLST profiles represented by more than one isolate included isolates from different clinical categories." (line 150-151)
It would be a good idea to ask someone outside of the research group to edit the paper. Such an individual without prior knowledge of the study results and methods would be able to quickly identify sentences that are unclear and need re writing.
Answer: We have asked a native American Chlamydia researcher to read and correct the manuscript. His name is Joseph Lyons and we have mentioned him in the acknowledgements.
3.
A weakness of this study is that the definitions of clinical categories used are based on patient histories only. Symptoms alone are relatively non specific for chlamydial infection. Was the Dutch study carried out specifically to collect chlamydia strains for genotyping or was this study done originally for other reasons? Since physical examination findings that could have more precisely categorized the patients were not used, I suspect that the specimens were collected for another purpose and that the study reported here was designed to make use of the available chlamydia isolates and whatever clinical data had been previously collected.
Answer: This study was collected specifically for having a culturable set of clinically well defined isolates. These isolates were obtained from a larger study in which NO culture was obtained from the other isolates, and this study aimed to study both host and bacterial factors in relation to the course of CT infections, thus the samples were not "just picked from another study" bacterial typing was already initially part of the aim. The way samples are collected based on the largest STD clinic in The Netherlands is that samples are collected initially based on the patient reportance on symptoms or reasons (Asymptomatic but wanting to check based on a new relation. This was also the way the METC allowed us to collect the samples.
This should be made clear in the methods section.
Answer: We have added additional information in the Methods section on the origin on the samples as suggested by the reviewer.(lines 95-109)
Then there should be a short "limitations" paragraph in the Discussion section. Here the authors should indicate that the negative findings in this study do not disprove that some stains of chlamydia are more virulent than others and could suggest that future studies should look at mucopurulent cervicitis and pelvic inflammatory disease using clearly defined examination findings to form clinical definitions.
Answer: We have not stated that the results disprove that there might be "some stains of chlamydia that are more virulent than others". Quite contrary, the discussion already contained the following sentence:
"The immune responses leading to symptoms and sequelae might be initiated by antigens encoded by other regions of the C. trachomatis genome..."
5.
Line 177: "The immune responses leading to symptoms and sequelae might be initiated by antigens encoded by other regions of the C. trachomatis genome?" What is meant by this phrase?
Are the authors referring to antigens encoded by genes other than those used for their MLST system? Answer: Yes. We consider the sentence to be quite clear, but since both reviewers ask questions about the same sentence it has now been rewritten in the manuscript (lines 178-181) Do MLST genes in their system code for proteins that are likely to be recognized by the host immune system? If so that should be stated.
Answer: It is already stated. In the introduction it says (lines 75-78): "The hctB gene encodes a histone H1-like protein that functions as a global regulator of chromatin structure and gene expression, while the pbpB gene encodes a penicillin binding protein that is a putative outer membrane protein potentially involved in the interaction with the host cell."
Generally it is assumed that a genotyping system is a surrogate for associated genes within a given strain variant that have virulence potential. Please clarify the intent of this phrase. Might want to just drop it. The first step is to find a correlation. The second step is to investigate exactly which changes in the genome correspond to the correlation. We did however not find a correlation, and have therefore not continued with the second step.
6.
Lines 186-190. This could be dropped. Discrimination index change from 3 to 2.5 is insignificant. This distracts from main points of the study Answer: We agree. This has now been excluded from the manuscript.
7.
The issue of utility of housekeeping genes vs. those chosen by these investigators for an MLST system is complex. Some would argue that the lower discriminatory index would be an advantage when searching for virulence factors as both would evolve slowly over time and perhaps more likely in parallel than more rapidly evolving genes. It is not clear to me which is better, but expanded discussion of this issue would be of interest to readers. It would also help explain to those not familiar with the issues surrounding developing MLST systems why the authors have brought the issue up in the first place.
Answer: We agree and have added this to the manuscript (lines 184-190).
8.
Lines194-96: This sentence could be part of your discussion of your MLST system vs. the housekeeping gene based systems.
Answer: Yes, it could. But we feel it also fits nicely where it is currently written.
Reviewer #2: This is an interesting paper which has clearly involved a considerable amount of work. However I am unconvinced by the rational behind it and given its size I am not surprised no association was found. It does however highlight the difficulties in undertaking genotyping studies with C. trachomatis in humans.
I have the following comments:
1)
The central hypothesis in this study seems to be that this type of study is able to provide information on how the immune response to the antigens studied may influence disease Answer: No. The central hypothesis in this study is that differences in the genetic composition of C. trachomatis strains can influence the development of urogenital disease. Pathogen specific genetic factors that unambiguously explain the pathogenesis of C. trachomatis have not yet been clearly identified. Therefore we decided to try previously untested genetic regions, i.e. the MLST target regions, in order investigate this hypothesis, by looking for a correlation between the MLST results and the clinical symptoms of disease. The last paragraph in the introduction has been slightly rephrased (lines 82-86) to avoid future misunderstandings.
-"the immune responses leading to symptoms and sequelae might be initiated by antigens encoded by other regions of the C. trachomatis genome, or it might be due to host specific innate immune responses, having nothing or little to do with strain specific antigens" (lines 177-9). I do not believe this is a reasonable assumption. For three reasons: a.
Answer
The association of disease is may be due to genetic linkage. For example genotyping C. trachomatis using MOMP reveals 3 distinct groups characterised by different disease patterns. The trachoma serovars are genetically linked to a defective tryptophan dehydrogenase gene which is likely to be important in pathogenesis [1, 2] .
LGV is a much more aggressive infection capable of infecting a much wider range of cells than serovars A-J and is associated with invasive disease. This is unlikely to be due to differences in the immune response to MOMP, it most likely is a consequence of genetic linkage to other genes which control replication dynamics and attachment although it may directly influence cell tropism as there is some evidence MOMP may be involved in cell attachment and entry.
[3] Thus pathogenesis of disease will be related to the immunobiology of the host pathogen interaction not just the immune response. Answer: We agree. As previously stated, the last paragraph in the introduction has been slightly rephrased (lines 82-86) to avoid future misunderstandings.
Given the number of genes present in C. trachomatis, MLST studies may identify association with disease directly related to those genes selected or as a consequence of genetic linkage.
Answer: We agree and this has not been contradicted anywhere in the article.
b.
The MLST profiles are likely to only be important in the immune response if they involve (or are linked) to critical B or T cell epitopes. Thus the failure to demonstrate an association with disease does not necessarily exclude these antigens as being important in the immune response. This is consistent with what we know about the immune response and MOMP serovar. 
c.
It is possible that these base pair differences could effect individual gene function and as a result change the biological characteristics of the isolate and thus its pathogenicity.
Answer: We agree that genetic variation could affect individual gene function and pathogenicity. That is the central hypothesis in this study and that is why the study has been performed.
Thus association of disease with distinct MLST patterns may be due to differences in the immune response but may also result from differences in cellular biology in vivo which may or may not be as a direct consequence of the gene being studied.
Answer: We agree and to avoid misunderstandings lines 62-64 in the introduction and, as previously mentioned, lines 178-181 in the discussion has been rewritten.
2.
Nevertheless important differences in clinical presentation may be related to C. trachomatis genotypes within serovars D-K. Although as stated the evidence is inconclusive, Geisler and colleagues have published on the potential interaction between serovar J/Ja and the immune system -being associated with early clearance. 
I.
With 46 MLST profiles it is my understanding that a very large number of clinical samples would be needed in order to identify a significant association with disease (which is not due to chance). Have you sought statistical advice on this-if so this should be explicit. It would be informative for the reader to know that as the discriminatory power of typing techniques increases the larger the number of characterised clinical samples required in order to reliably demonstrate a significant association. 
b.
No evidence is presented to suggest that the 5 genes selected for MLST analysis are likely to be important in the immunobiology of infection. My understanding is that this typing system is primarily of value "in transmission studies and network analyses, where high resolution is needed to tell closely related strains apart." (discussion lines 194-6). Surely for the purposes of this study as stated, it would be sensible to use genes which are known (or believed to be) important in the immunobiology of disease based on in vitro and animal studies-(I acknowledge that this is an area which remains poorly understood but it should be discussed)
Answer: Pathogen specific antigens unambigously explaining the pathogenesis of C. trachomatis are still poorly identified. Therefore, instead of trying targets that have already been investigated, we decided to try novel targets, i.e. the MLST target regions, to see if we could find a correlation to clinical symptoms. In the introduction we explain that: "The hctB gene encodes a histone H1-like protein that functions as a global regulator of chromatin structure and gene expression, while the pbpB gene encodes a penicillin binding protein that is a putative outer membrane protein potentially involved in the interaction with the host cell." (lines 75-78) It might have been a long shot to try and correlate the MLST target regions to symptoms, but in our opinion, still worth a try.
II.
Relating symptoms to disease is complex in C. trachomatis infection. Vaginal discharge is non-specific and often due to other aetiologies such as bacterial vaginosis. Abdominal pain is also non-specifc, as you have acknowledged in previous communications [7] . Where the women recruited examined? Details are only provided of clinical symptoms. It would be helpful to know if those with abdominal pain had clinical PID. 
III.
Given that culture is only 60-80% sensitive it is possible that the isolates obtained by culture were biased and may reflect growth characteristics associated with easier propogation in culture. Do you have any details of those women sampled who were culture negative? Where women tested by a NAAT and is any specimen available from those NAAT-positive culture negative? Did the proportion vary by symptom group? I would expect asymptomatic women to have lower chlamydial loads to be less likely to be culture positive[9, 10].
Answer: The culture efficiency was not different between symptomatic and asymptomatic cases and very high both to very stringent sample collection procedures having the samples directly frozen at -80C as well as the presence of 2 different samples to use for culture. There can be a slight though non significant selection since we selected such that we represented all urogenital serovars in the selection of strains. In addition we feel that the course of infection is not only a bacterial load issue but also a host issue based on how you combat infection based on your genetic make-up.
In conclusion although I agree with your conclusion that to "better understand the clinical course of infection future studies should not only consider bacterial factors but also look more on the immunogenetics of the host." I do not believe that the data as currently presented supports such a statement. Essentially we need very large studies, ideally using isolates from patients with well characterised clinical presentations which also includes human genotyping.
Given the likely size this will need to be multi-centre, multidisciplinary and almost certainly international.
Answer: We completely agree with the reviewer that that question can only we answered by collecting very large cohorts collected in a multi centre approach. This is what is exactly done by the European Union funded EpiGenChlamydia Consortium which is cited in the Sources of support, but we have now also stated this in the discussion as suggested by the reviewer. The MLST system had a 2.5 fold higher resolution than ompA genotyping in this study, 216 which is lower than the 3.0 fold higher resolution shown in previous studies. This is due to 217 the low number of serotype E strains included in this study. Serotype E is usually the most 218 prevalent serotype in genital tract infections and it is where the MLST system previously 219 has been the most discriminatory compared to ompA genotyping. , though 236 it appears that host factors contribute to a much higher degree. The European Union has 237 funded the EpiGenChlamydia Consortium, which is led by Dr. Morré, and is in the process 238 of creating large biobanks of patient derived and bacterial specimens on which to perform 239 
RESULTS

145
The 70 C. trachomatis isolates could be separated into 46 MLST genotypes whereas the 146 conventional ompA genotyping system identified 18 genotypes (Table 1) . Overall, the 147 MLST system had a 2.5 fold higher resolution than conventional ompA genotyping. The 148 MLST resolution was seven and six fold higher within serovar K and E respectively. MLST 149 profile number 34 was found in both serovar D and H. responses to C. trachomatis infection can be ascribed to host genetic factors. 16 The 207 differences in the clinical course of infection are due to an interplay of both bacterial and 208 host genetic factors and both should be taken into account in future studies 17, 18 , though it 209 appears that host factors contribute to a much higher degree. The European Union has 210 funded the EpiGenChlamydia Consortium, which is led by Dr. Morré, and is in the process 211 of creating large biobanks of patient derived and bacterial specimens on which to perform 212 studies to determine bacterial and host factors that play a role in the course of infection with 213 chlamydia. 
